PARIS, Sept 20 – Over the past few months analysts and experts have been scratching their heads, wondering if leading proteomics company Oxford Glycosciences (LSE: OGS) was losing its edge.

The company appeared to have a poor business plan, a weak drug development pipeline, and little response as companies such as Celera Genomics (NYSE: CRA) and Swiss start-up Geneva Proteomics announced their intentions to dominate the proteomics space.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.